How will you counsel your patient who is taking a NOAC lifelong- but has a strong preference not to- when they ask you about the choice of LAAC vs. NOAC? On behalf of my co-investigators, I will present late-breaking science
#ESCCongress 2026 in Munich to further answer this question.
This meta-analysis by
@DFCapodanno @LaudaniClaudio and others includes the landscape of
#LAAC trials from the past two decades. A similar one was published in
#JACC Clin EP this year.
Current
@ACCinTouch @escardio guidelines encourage NOAC over warfarin, making PROTECT and PREVAIL- using warfarin as a comparator, with a prior device iteration- less relevant.
Other, more recent trials included in the meta-analyses focus on higher risk patients with great medical complexity. Contemporary devices and techniques have led to improved safety, with National Cardiovascular Data Registry (NCDR) SURPASS Registry supporting real-world complications lower than 1%.
lnkd.in/ggw6kMHT
For patients with
#AF who are indicated for lifelong
#OAC (i.e. higher CHADS2VASC, lower bleeding risk), with today's contemporary devices and medications: what is the relevant data to inform patient-centered
#shareddecisionmaking? Join me Monday August 31 at 1:00 pm for what is sure to be a passionate discussion.
No free lunch. In our meta-analysis, now published in JAMA Cardiology, transcatheter left atrial appendage closure (LAAC) was associated with similar long-term risks of any stroke and major bleeding compared with oral anticoagulation in patients with atrial fibrillation, while increasing the risk of ischemic stroke and reducing the risk of nonprocedure-related major bleeding.
Article:
jamanetwork.com/journals/jam…
Editorial:
jamanetwork.com/journals/jam…